Dina Pharma was founded by a team of world-renowned doctors, scientists, and academics with a singular goal: to improve the quality of life of patients suffering from Parkinson's disease. We are introducing an innovative, new therapy, DPI-289, which improves efficacy and reduces the side effects of the primary treatment for Parkinson's disease.
What is Parkinson's disease? Parkinson’s disease (PD) is a chronic, severe, and progressive neurodegenerative disorder resulting from the loss of dopamine-producing neurons. About 1 million people have PD in the U.S., only 50% of whom are diagnosed. PD is the most prevalent neuro-degenerative disorder after Alzheimer’s.
How is PD currently treated? 50 years after its discovery, levodopa, remains the gold standard in PD treatment. Within 3 years of starting levodopa, as many as 40% of patients develop a disabling side-effect known as levodopa-induceddyskinesia(LID). LID – characterized by involuntary, non-rhythmic, purposeless, and unpredictable movements – severely degrades quality of life and increases treatment costs. Brain surgery is the only option for patients who cannot tolerate levodopa or LID.LID is recognized by the FDA as an orphan disease state.No novel approved therapies for LID currently exist.
As a result, patients too often face a terrible choice between treating their Parkinson's symptoms and enduring Levodopa-induced dyskinesia. Experts in Parkinson's disease research have found that “LID is the most important unmet medical need in the treatment of PD.”
Dina Pharma's lead drug, DPI-289, provides a solution Dina Pharma is a pre-IND stage biotech advancing our lead asset, DPI-289, a small-molecule new chemical entity that targets a novel pathway in Parkinson's disease. Our compelling efficacy data in gold standard non-human primate models of PD showcases the therapeutic potential of DPI-289. DPI-289 is a first-in-class DAMA compound that targets specific subtypes of opioid receptors (delta agonist, mu antagonist). Both rodent and non-human primate disease models indicate that DPI-289 can treat PD symptoms as monotherapy, or in combination with levodopa therapy to reduce or eliminate LID.
Dina Pharma is developing a treatment for Levodopa-Induced Dyskinesia (LID), to transform the lives of patients with Parkinson's disease.